Fidelity Advisor Biotechnology FundFBTCX
Type
Mutual fund
Peer group
US equity: Healthcare
Net assets
$1.9B
Expense ratio
1.71%
1-year return
+65.3%
3 years, a year
+21.2%
5 years, a year
+2.9%
12-month yield
1.35%
Holdings
98
What it aims to do.
Fidelity Advisor Biotechnology Fund seeks capital appreciation.
Top 10 holdings.
| Holding | % of fund |
|---|---|
| ABBV Abbvie Inc | 14.83% |
| ALNY Alnylam Pharmaceuticals Inc | 5.52% |
| GILD Gilead Sciences Inc | 5.42% |
| INSM Insmed Inc | 3.51% |
| COGT Cogent Biosciences Inc | 3.45% |
| DNTH Dianthus Therapeutics Inc | 3.37% |
| SYRE Spyre Therapeutics Inc | 3.33% |
| Ascendis Pharma A/S | 3.24% |
| ARGX Argenx Se | 3.17% |
| BIIB Biogen Inc | 2.93% |
More on FBTCX.
- FBTCX overview
- FBTCX holdings
- FBTCX risk
- FBTCX costs
- FBTCX money in and out
- FBTCX share classes
- Compare FBTCX with other funds
Returns after fees, from the fund's SEC filings up to Aug 2026. Past returns are not a promise. Not financial advice.